SG11201504943QA - Prolactin receptor binding proteins and uses thereof - Google Patents

Prolactin receptor binding proteins and uses thereof

Info

Publication number
SG11201504943QA
SG11201504943QA SG11201504943QA SG11201504943QA SG11201504943QA SG 11201504943Q A SG11201504943Q A SG 11201504943QA SG 11201504943Q A SG11201504943Q A SG 11201504943QA SG 11201504943Q A SG11201504943Q A SG 11201504943QA SG 11201504943Q A SG11201504943Q A SG 11201504943QA
Authority
SG
Singapore
Prior art keywords
binding proteins
receptor binding
prolactin receptor
prolactin
proteins
Prior art date
Application number
SG11201504943QA
Inventor
Mark Anderson
Jieyi Wang
Archana Thakur
Debra Chao
Chung-Ming Hsieh
Qian Zhang
Edward B Reilly
Enrico L Digiammarino
Kenton L Longenecker
Russell A Judge
David A Egan
Charles W Hutchins
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of SG11201504943QA publication Critical patent/SG11201504943QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01S—RADIO DIRECTION-FINDING; RADIO NAVIGATION; DETERMINING DISTANCE OR VELOCITY BY USE OF RADIO WAVES; LOCATING OR PRESENCE-DETECTING BY USE OF THE REFLECTION OR RERADIATION OF RADIO WAVES; ANALOGOUS ARRANGEMENTS USING OTHER WAVES
    • G01S13/00—Systems using the reflection or reradiation of radio waves, e.g. radar systems; Analogous systems using reflection or reradiation of waves whose nature or wavelength is irrelevant or unspecified
    • G01S13/86—Combinations of radar systems with non-radar systems, e.g. sonar, direction finder
    • G01S13/867—Combination of radar systems with cameras
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01S—RADIO DIRECTION-FINDING; RADIO NAVIGATION; DETERMINING DISTANCE OR VELOCITY BY USE OF RADIO WAVES; LOCATING OR PRESENCE-DETECTING BY USE OF THE REFLECTION OR RERADIATION OF RADIO WAVES; ANALOGOUS ARRANGEMENTS USING OTHER WAVES
    • G01S13/00—Systems using the reflection or reradiation of radio waves, e.g. radar systems; Analogous systems using reflection or reradiation of waves whose nature or wavelength is irrelevant or unspecified
    • G01S13/88—Radar or analogous systems specially adapted for specific applications
    • G01S13/91—Radar or analogous systems specially adapted for specific applications for traffic control
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V20/00—Scenes; Scene-specific elements
    • G06V20/50—Context or environment of the image
    • G06V20/56—Context or environment of the image exterior to a vehicle by using sensors mounted on the vehicle
    • G06V20/58—Recognition of moving objects or obstacles, e.g. vehicles or pedestrians; Recognition of traffic objects, e.g. traffic signs, traffic lights or roads
    • G—PHYSICS
    • G08—SIGNALLING
    • G08G—TRAFFIC CONTROL SYSTEMS
    • G08G1/00—Traffic control systems for road vehicles
    • G08G1/01—Detecting movement of traffic to be counted or controlled
    • G08G1/0104—Measuring and analyzing of parameters relative to traffic conditions
    • G08G1/0125—Traffic data processing
    • G—PHYSICS
    • G08—SIGNALLING
    • G08G—TRAFFIC CONTROL SYSTEMS
    • G08G1/00—Traffic control systems for road vehicles
    • G08G1/01—Detecting movement of traffic to be counted or controlled
    • G08G1/015—Detecting movement of traffic to be counted or controlled with provision for distinguishing between two or more types of vehicles, e.g. between motor-cars and cycles
    • G—PHYSICS
    • G08—SIGNALLING
    • G08G—TRAFFIC CONTROL SYSTEMS
    • G08G1/00—Traffic control systems for road vehicles
    • G08G1/01—Detecting movement of traffic to be counted or controlled
    • G08G1/04—Detecting movement of traffic to be counted or controlled using optical or ultrasonic detectors
    • G—PHYSICS
    • G08—SIGNALLING
    • G08G—TRAFFIC CONTROL SYSTEMS
    • G08G1/00—Traffic control systems for road vehicles
    • G08G1/01—Detecting movement of traffic to be counted or controlled
    • G08G1/042—Detecting movement of traffic to be counted or controlled using inductive or magnetic detectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Radar, Positioning & Navigation (AREA)
  • Remote Sensing (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Electromagnetism (AREA)
  • Analytical Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Multimedia (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201504943QA 2012-12-24 2013-12-23 Prolactin receptor binding proteins and uses thereof SG11201504943QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261745707P 2012-12-24 2012-12-24
PCT/US2013/077452 WO2014105810A1 (en) 2012-12-24 2013-12-23 Prolactin receptor binding proteins and uses thereof

Publications (1)

Publication Number Publication Date
SG11201504943QA true SG11201504943QA (en) 2015-07-30

Family

ID=49956483

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201504943QA SG11201504943QA (en) 2012-12-24 2013-12-23 Prolactin receptor binding proteins and uses thereof

Country Status (29)

Country Link
US (4) US9725515B2 (en)
EP (2) EP2935331B1 (en)
JP (3) JP6382221B2 (en)
KR (1) KR20150100881A (en)
CN (1) CN105102480B (en)
AU (3) AU2013370548B2 (en)
BR (1) BR112015015289A2 (en)
CA (1) CA2896058A1 (en)
CY (1) CY1120286T1 (en)
DK (1) DK2935331T3 (en)
ES (1) ES2671506T3 (en)
HK (1) HK1216257A1 (en)
HR (1) HRP20180822T1 (en)
HU (1) HUE037586T2 (en)
IL (1) IL239502B (en)
LT (1) LT2935331T (en)
ME (1) ME03075B (en)
MX (1) MX359532B (en)
NO (1) NO2968312T3 (en)
PL (1) PL2935331T3 (en)
PT (1) PT2935331T (en)
RS (1) RS57259B1 (en)
RU (2) RU2018129572A (en)
SG (1) SG11201504943QA (en)
SI (1) SI2935331T1 (en)
TR (1) TR201807416T4 (en)
TW (3) TW201920245A (en)
WO (1) WO2014105810A1 (en)
ZA (1) ZA201504803B (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130280282A1 (en) * 2012-04-24 2013-10-24 Daiichi Sankyo Co., Ltd. Dr5 ligand drug conjugates
PT2935331T (en) 2012-12-24 2018-06-04 Abbvie Inc Prolactin receptor binding proteins and uses thereof
TWI641620B (en) * 2013-08-21 2018-11-21 再生元醫藥公司 Anti-prlr antibodies and uses thereof
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
AU2014342610A1 (en) 2013-11-04 2016-06-02 Abbvie Stemcentrx Llc Anti-EFNA4 antibody-drug conjugates
JO3663B1 (en) * 2014-08-19 2020-08-27 Merck Sharp & Dohme Anti-lag3 antibodies and antigen-binding fragments
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
HUE061672T2 (en) 2014-11-12 2023-08-28 Seagen Inc Glycan-interacting compounds and methods of use
KR20180020277A (en) * 2015-06-24 2018-02-27 제이씨알 파마 가부시키가이샤 Anti-Human Transferrin Receptor Antibody Passing Through the Blood Brain Gate
WO2016208696A1 (en) 2015-06-24 2016-12-29 Ｊｃｒファーマ株式会社 Fusion protein containing bdnf
CN108472369A (en) 2015-11-03 2018-08-31 詹森生物科技公司 The subcutaneous preparations and application thereof of 8 antibody of AntiCD3 McAb
JP7066613B2 (en) * 2015-11-12 2022-05-13 シージェン インコーポレイテッド Glycan interacting compounds and how to use
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
CN106265480A (en) * 2016-09-03 2017-01-04 山西纳安生物科技有限公司 Nano antibody vaginal drug delivery systems and preparation method and application
KR20230114331A (en) 2016-09-14 2023-08-01 애브비 바이오테라퓨틱스 인크. Anti-pd-1 antibodies and their uses
US10711032B2 (en) 2016-11-08 2020-07-14 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
KR20190091290A (en) * 2016-11-29 2019-08-05 리제너론 파아마슈티컬스, 인크. How to Treat PrLr Positive Breast Cancer
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
BR112019009316A2 (en) 2016-12-26 2019-08-06 Japan Chem Res human transferrin anti-receptor antibody, fusion protein, DNA fragment, expression vector, mammalian cell, pharmacologically active compound and human transferrin anti-receptor antibody complex, uses of human transferrin anti-receptor antibody and fusion protein, and, methods for treating a central nervous system disorder and a central nervous system disorder accompanying pompe disease, hurler syndrome or hurler-scheie syndrome.
KR102471458B1 (en) 2016-12-28 2022-11-25 제이씨알 파마 가부시키가이샤 Freeze-dried formulation
KR102653141B1 (en) 2017-03-03 2024-04-01 씨젠 인크. Glycan-interacting compounds and methods of use
CA3053649A1 (en) * 2017-03-20 2018-09-27 Vaccinex, Inc. Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent
TW201836647A (en) 2017-04-06 2018-10-16 美商艾伯維有限公司 Anti-prlr antibody-drug conjugates (adc) and uses thereof
SG11201909708VA (en) * 2017-04-21 2019-11-28 Mellitus Llc Methods and antibodies for diabetes-related applications
AU2018270784B2 (en) 2017-05-18 2024-05-16 Regeneron Pharmaceuticals, Inc. Cyclodextrin protein drug conjugates
US11351140B2 (en) 2017-05-19 2022-06-07 J. Craig Venter Institute Resolvin mimetic antibodies and uses thereof
CN117700548A (en) * 2017-08-03 2024-03-15 艾利妥 anti-CD 33 antibodies and methods of use thereof
SG11202006510XA (en) 2018-01-08 2020-08-28 Regeneron Pharma Steroids and antibody-conjugates thereof
WO2019169330A1 (en) * 2018-03-02 2019-09-06 Oncolix, Inc. Method for treating cancers expressing prolactin receptor
US10285998B1 (en) 2018-04-04 2019-05-14 The Menopause Method, Inc. Composition and method to aid in hormone replacement therapy
CN113226367A (en) 2018-04-06 2021-08-06 Atyr 医药公司 Compositions and methods comprising anti-NRP 2 antibodies
KR20210008008A (en) 2018-05-09 2021-01-20 리제너론 파마슈티칼스 인코포레이티드 Anti-MSR1 antibodies and methods of use thereof
KR102646145B1 (en) 2018-05-31 2024-03-11 주식회사 엑소코바이오 Composition for reducing skin pore size comprising an exosome derived from stem cell as an active ingredient
WO2020027466A1 (en) 2018-07-28 2020-02-06 주식회사 엑소코바이오 Method for lyophilizing exosome
KR102163806B1 (en) * 2018-07-30 2020-10-07 주식회사 엑소코바이오 Composition for reducing sebum release comprising an exosome derived from stem cell as an active ingredient
MX2021001254A (en) * 2018-07-31 2021-05-12 Cullinan Mica Corp Anti-mica/b antibodies that block mica/b shedding and methods of use.
WO2020181376A1 (en) * 2019-03-12 2020-09-17 University Health Network Tsg-6 antibodies and uses therefor
EP3757217A1 (en) * 2019-06-27 2020-12-30 GlaxoSmithKline Biologicals S.A. Methods for protein purification
EP3992209A4 (en) * 2019-07-12 2023-01-18 Futuregen Biopharmaceutical (Beijing) Co., Ltd. Cldn18.2 antibody and use thereof
RU2722398C1 (en) * 2019-08-09 2020-05-29 Федеральное государственное унитарное предприятие «Государственный научно-исследовательский институт особо чистых биопрепаратов» Федерального медико-биологического агентства Monoclonal antibody to heat shock protein 70
US11807687B2 (en) 2019-10-03 2023-11-07 Atyr Pharma, Inc. Therapeutic compositions comprising anti-NRP2 antibodies
AU2021264094A1 (en) * 2020-04-30 2022-11-24 Board Of Regents, The University Of Texas System Anti-CD79b antibodies and chimeric antigen receptors and methods of use thereof
UY39610A (en) 2021-01-20 2022-08-31 Abbvie Inc ANTI-EGFR ANTIBODY-DRUG CONJUGATES
WO2022266539A2 (en) * 2021-06-18 2022-12-22 Therini Bio, Inc. ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE
EP4423142A1 (en) * 2021-10-27 2024-09-04 aTyr Pharma, Inc. Compositions and methods comprising anti-nrp2a antibodies
CN115417908B (en) * 2022-09-01 2024-06-18 英科新创（苏州）生物科技有限公司 Estradiol derivative, preparation method thereof, detection kit and estradiol quantitative detection method
CN115353541B (en) * 2022-09-01 2024-06-18 英科新创（苏州）生物科技有限公司 Process for the preparation of estradiol derivatives, intermediates, process for the preparation thereof and use thereof
CN117694469B (en) * 2024-02-02 2024-04-23 潍坊新希望六和饲料科技有限公司 Feed additive for improving quality of eggshells of brown-shell eggs

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867187B2 (en) 2000-12-22 2005-03-15 Trustees Of The University Of Pennsylvania Composition and method for modulating somatolactogenic function
US7507716B2 (en) 2005-07-06 2009-03-24 Board Of Regents, The University Of Texas System Method for treating pain with prolactin antagonists
US7422899B2 (en) * 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
TWI454480B (en) 2006-08-18 2014-10-01 Novartis Ag Prlr-specific antibody and uses thereof
US8648046B2 (en) 2009-02-26 2014-02-11 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
JP5963443B2 (en) 2009-02-26 2016-08-03 オンコリックス， インコーポレイテッド Compositions and methods for visualizing and eliminating cancer stem cells
EP2332995A1 (en) 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
US20130244936A1 (en) 2010-06-04 2013-09-19 Vincent Goffin Constitutively active prolactin receptor variants as prognostic markers and therapeutic targets to prevent progression of hormone-dependent cancers towards hormone-independence
WO2012136519A1 (en) 2011-04-06 2012-10-11 Bayer Pharma Aktiengesellschaft Use of neutralizing prolactin receptor antibodies for the treatment and prevention of antiestrogen-resistant breast cancer
EP2530089A1 (en) * 2011-06-03 2012-12-05 Bayer Pharma Aktiengesellschaft Neutralising prolactin receptor antibody Mat3 and its therapeutical use
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
PT2935331T (en) 2012-12-24 2018-06-04 Abbvie Inc Prolactin receptor binding proteins and uses thereof
TWI641620B (en) 2013-08-21 2018-11-21 再生元醫藥公司 Anti-prlr antibodies and uses thereof
CA2950155C (en) 2014-06-02 2021-11-23 Regeneron Pharmaceuticals, Inc. Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses

Also Published As

Publication number Publication date
HUE037586T2 (en) 2018-09-28
US20170022281A1 (en) 2017-01-26
US20190153110A1 (en) 2019-05-23
MX2015008299A (en) 2016-02-11
WO2014105810A1 (en) 2014-07-03
CN105102480B (en) 2019-04-16
US9725515B2 (en) 2017-08-08
EP3363817A1 (en) 2018-08-22
LT2935331T (en) 2018-06-25
ES2671506T3 (en) 2018-06-06
TW201920283A (en) 2019-06-01
DK2935331T3 (en) 2018-06-06
AU2019202725A1 (en) 2019-05-16
EP2935331A1 (en) 2015-10-28
JP2018198608A (en) 2018-12-20
TW201920245A (en) 2019-06-01
CA2896058A1 (en) 2014-07-03
US20210074147A1 (en) 2021-03-11
TR201807416T4 (en) 2018-06-21
JP6382221B2 (en) 2018-08-29
PT2935331T (en) 2018-06-04
JP2016504035A (en) 2016-02-12
RS57259B1 (en) 2018-08-31
TW201441259A (en) 2014-11-01
RU2015130605A (en) 2017-01-24
US20210312797A9 (en) 2021-10-07
EP2935331B1 (en) 2018-02-28
PL2935331T3 (en) 2018-07-31
CY1120286T1 (en) 2019-07-10
HRP20180822T1 (en) 2018-08-10
IL239502A0 (en) 2015-08-31
RU2664463C2 (en) 2018-08-17
BR112015015289A2 (en) 2017-08-15
RU2018129572A (en) 2018-10-12
NO2968312T3 (en) 2018-06-30
AU2013370548B2 (en) 2019-01-17
US10184003B2 (en) 2019-01-22
SI2935331T1 (en) 2018-06-29
KR20150100881A (en) 2015-09-02
AU2013370548A1 (en) 2015-07-09
MX359532B (en) 2018-10-01
ME03075B (en) 2019-01-20
JP2020188775A (en) 2020-11-26
ZA201504803B (en) 2020-02-26
HK1216257A1 (en) 2016-10-28
TWI646106B (en) 2019-01-01
IL239502B (en) 2019-11-28
AU2021202954A1 (en) 2021-06-03
CN105102480A (en) 2015-11-25
US20140227294A1 (en) 2014-08-14

Similar Documents

Publication Publication Date Title
HK1216257A1 (en) Prolactin receptor binding proteins and uses thereof
HK1205136A1 (en) Cdim binding proteins and uses thereof cdim
HRP20190358T1 (en) Anti-asic1 antibodies and uses thereof
HK1208687A1 (en) Rspo3 binding agents and uses thereof rspo3
HK1198832A1 (en) Fn14 binding proteins and uses thereof fn14
ZA201405554B (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
EP2558500A4 (en) Proteins that bind pi16 and uses thereof
HK1210182A1 (en) Anti-prokineticin receptor (prokr) antibodies and uses thereof (prokr)
EP2817324A4 (en) Nemo binding domain fusion proteins
GB201208372D0 (en) Antibodies and uses thereof
GB201203944D0 (en) Binding polypeptides